Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, October 19, 2015
Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in the Lancet Oncology
Monday, October 5, 2015
Eisai to Provide Diethylcarbamazine Citrate Tablets Free of Charge for Use in National Lymphatic Filariasis Elimination Campaign in Indonesia
Tuesday, September 29, 2015
Eisai Receives Additional Approval in Japan for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations
U.S. FDA Grants Priority Review Status to sNDA for Anticancer Agent Halaven as Treatment for Soft Tissue Sarcoma
Friday, September 25, 2015
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China
Monday, September 14, 2015
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress
Thursday, September 10, 2015
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease
Friday, July 31, 2015
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)"
Wednesday, July 29, 2015
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: